Skip to main content
Clinical Trials/NCT04796571
NCT04796571CompletedNot Applicable

Care Coordination and Proactive Care to Improve Utilization of Resources and Reduce Expenditure in High Risk Inflammatory Bowel Disease (IBD) Patients

University of Michigan1 site in 1 country425 target enrollmentStarted: January 1, 2019Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Enrollment
425
Locations
1
Primary Endpoint
IBD-related charges per person

Study Overview

Brief Summary

The study team performed a randomized controlled trial to evaluate the efficacy of a care coordination intervention composed of proactive symptom monitoring and algorithm-based triggers to improve patient reported outcomes (PROs) and healthcare expenditures for high-risk patients with IBD. Enrolled patients with IBD were randomized to proactive symptom monitoring with the support of a care coordinator or usual care.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Supportive Care
Masking
Double (Investigator, Outcomes Assessor)

Masking Description

Blinding of participants was not possible because telephone visits were only offered to participants in the intervention arm. Investigators were blinded to the randomization order, but patients, staff, and providers were not blinded to arm assignment. The investigators who validated the data and performed the data analysis remained blinded to patient group assignment.

Eligibility Criteria

Ages
18 Years to 90 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • established diagnosis of IBD (with at least 3 office visits)
  • followed in GI clinic within 1 year of enrollment
  • in top 20th percentile of predicted risk for subsequent healthcare utilization (previously validated model)

Exclusion Criteria

  • non-IBD driver for high utilization (e.g., active cancer undergoing treatment
  • A life expectancy of less than one year, were excluded from participation.

Arms & Interventions

Care Coordination Arm

Experimental

Patients were assigned an IBD-focused care coordinator who facilitated a symptom-based monitoring algorithm and supported patient navigation to complement usual care.

Intervention: Proactive Symptom Monitoring and Care Coordination (Behavioral)

Usual Care

No Intervention

Participants in the usual care arm underwent symptom monitoring through regular push notifications to participants to complete a validated PRO instrument through the Epic EMR patient portal or telephone. These notifications were scheduled on a monthly basis. Results of the monthly PRO instrument were available to their treating IBD doctor with interventions at their discretion.

passive control arn

No Intervention

To explore whether our usual care arm was influenced by the monthly PRO measurements required for examination of our primary outcome, we compared IBD charges, total charges, ED visits, hospitalizations, and medication utilization at 12 months in the usual care arm to a passive control arm consisting of patients who met eligibility criteria, but were not enrolled in the intervention or usual care arms.

Outcomes

Primary Outcomes

IBD-related charges per person

Time Frame: 12 months

extracted charges where IBD was the primary diagnosis over study period

Change in patient reported outcome (PRO) scores

Time Frame: 9 months

Patient Reported Outcome (PRO) measurements were administered on a monthly basis. The validated Crohn's (CD)-PRO or ulcerative colitis (UC)-PRO were used according to the patient's IBD type (Crohn's or ulcerative colitis). Both the CD-PRO and UC-PRO are a set of standardized and validated instruments based on the Crohn's Disease Activity Index and Mayo Clinic Score respectively, which includes six domains: daily bowel movements, functional symptoms, systemic symptoms, daily coping, weekly life impact, and weekly emotional impact. Scores are calculated a composite score across all domains where a score of 0 represents no symptom activity and a score of 40 represents the highest possible symptom burden. These were not two separate outcomes, rather two independent measurement instruments (scored on the same scale) specific to the patient's IBD-type to address the specific needs/concerns of the patients based on disease type.

Total healthcare charges per person

Time Frame: 12 months

all extracted charges over study period

Secondary Outcomes

  • Proportion of hospitalizations per person(12 months)
  • Emergency Department (ED) visits per person(12 months)
  • Change in IBD medication utilization(12 months)

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Peter Higgins

Professor of Internal Medicine

University of Michigan

Study Sites (1)

Loading locations...

Similar Trials